I was about to leave but one of the moderators encouraged me to stay, in spite of a a few negative posts questioning my credentials, I sent a few PM but have not heard back so I decided to copy/ paste. I don't want to sound self promoting but my reputation is important to me. Here goes:
The authors on the manuscript are mostly scientists with no financial interest in cydy, but NP is listed on the author list, and does not have a scientific background. Unfortunately this can slow down the editorial process. On a positive note Kush Dhody from Amarex has created a good study design. In my humble opinion you and fellow investors could go through the public portal of the FDA and express your concerns as investors in regard to the delay in the of BLA process. Your disappointments in the journals could be expressed once you are subscriber, in a letter to the editorial board. Not sure but you may need to provide a NPI number.
Addressing your concerns of my background, I graduated from University of Michigan 1980, worked in a P3 virology lab studying malignant trans formation or mouse 3T3 cells using SV40 vector, harvesting DNA then using restriction endo nucleases to cleave the DNA tagged with P32 isotope and using gel electrophoresis to examine the introns. Then I changed paths and graduated from Wayne Medical School in 1986. On to a surgical residency at William Beaumont finishing in 1991, then a private surgical practice being one the highest volume practices in Michigan. The hospital was the number one in terms of volume in the US.
In the middle of my career I worked with a small pharma company to shepherd their entereg through FDA approval. Then I became a consultant to Gore industries to develop a new hernia patch, my work gained attention and I was appointed to the board of the American Hernia Society and reviewed 8-10 manuscripts monthly. I presented at our meetings from the podium with an audience of 500. I also became a consultant to another small company that developed the drug Orfrimiv. I have published around 10 papers.
My cousin, chair of breast oncology at MD anderson was the PI on the discovery of HER2, and a self taught molecular biologist, with fascinating projects and has had molecules approved by the FDA, a very painful process. A couple have become block busters, but he never invested in these companies, nor did I.
I retired 2 years ago but have been a serious investor for 35 years, believe in the efficient market hypothesis, fundamentals using the accounting model. I am not bragging but most of my different stylistic accounts, the better ones showing gains of 30-40%
I hope this suffices to lend credibility, and quell your suspicions of my education.
My posts are my opinions based on my experiences and not meant to attack other members or CYDY. I understand you may disagree with my point of view.
Read More: https://investorshangout.com/messages/view?id...z6RwNZfn3d
The authors on the manuscript are mostly scientists with no financial interest in cydy, but NP is listed on the author list, and does not have a scientific background. Unfortunately this can slow down the editorial process. On a positive note Kush Dhody from Amarex has created a good study design. In my humble opinion you and fellow investors could go through the public portal of the FDA and express your concerns as investors in regard to the delay in the of BLA process. Your disappointments in the journals could be expressed once you are subscriber, in a letter to the editorial board. Not sure but you may need to provide a NPI number.
Addressing your concerns of my background, I graduated from University of Michigan 1980, worked in a P3 virology lab studying malignant trans formation or mouse 3T3 cells using SV40 vector, harvesting DNA then using restriction endo nucleases to cleave the DNA tagged with P32 isotope and using gel electrophoresis to examine the introns. Then I changed paths and graduated from Wayne Medical School in 1986. On to a surgical residency at William Beaumont finishing in 1991, then a private surgical practice being one the highest volume practices in Michigan. The hospital was the number one in terms of volume in the US.
In the middle of my career I worked with a small pharma company to shepherd their entereg through FDA approval. Then I became a consultant to Gore industries to develop a new hernia patch, my work gained attention and I was appointed to the board of the American Hernia Society and reviewed 8-10 manuscripts monthly. I presented at our meetings from the podium with an audience of 500. I also became a consultant to another small company that developed the drug Orfrimiv. I have published around 10 papers.
My cousin, chair of breast oncology at MD anderson was the PI on the discovery of HER2, and a self taught molecular biologist, with fascinating projects and has had molecules approved by the FDA, a very painful process. A couple have become block busters, but he never invested in these companies, nor did I.
I retired 2 years ago but have been a serious investor for 35 years, believe in the efficient market hypothesis, fundamentals using the accounting model. I am not bragging but most of my different stylistic accounts, the better ones showing gains of 30-40%
I hope this suffices to lend credibility, and quell your suspicions of my education.
My posts are my opinions based on my experiences and not meant to attack other members or CYDY. I understand you may disagree with my point of view.
Read More: https://investorshangout.com/messages/view?id...z6RwNZfn3d
12
